Cellular Therapy in NSCLC: Between Myth and Reality.

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Non-small cell lung carcinoma (NSCLC) remains a significant challenge in oncology.
• Adoptive cell therapies (ACT) have revolutionized hematologic malignancy treatment.
• The application of ACT in solid tumors, including NSCLC, is still under investigation.

Purpose of the Study:

• To review the current status and modalities of ACT for NSCLC.
• To discuss existing barriers to ACT implementation in NSCLC.
• To explore strategies for overcoming these challenges in NSCLC treatment.

Main Methods:

• Review of ongoing clinical trials for T cell-based ACT in NSCLC.
• Analysis of three primary ACT modalities: tumor-infiltrating lymphocytes (TILs), T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells.
• Examination of limitations and potential solutions for ACT in solid tumors.

Main Results:

• Several ACT trials are underway for NSCLC, focusing on TILs, TCRs, and CAR T cells.
• CAR T-cell efficacy in solid tumors like NSCLC is currently limited compared to hematologic cancers.
• Key limitations include severe toxicities, poor tumor infiltration, antigen escape, and manufacturing hurdles.

Conclusions:

• ACT holds promise for improving outcomes in metastatic NSCLC.
• Significant translational and clinical research is required to enhance ACT efficacy and application in NSCLC.
• Addressing current limitations is essential for unlocking the full potential of ACT for lung cancer patients.